Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03

Quynh-Thu Le; Jonathan Harris; Anthony M Magliocco; Christina S Kong; Roman Diaz; Brian Shin; Hongbin Cao; Andy Trotti; Janine Terra Erler; Christine H Chung; Adam Dicker; Thomas F Pajak; Amato J Giaccia; K Kian Ang

doi:10.1200/JCO.2008.20.6003

Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03

Quynh-Thu Le, Jonathan Harris, Anthony M Magliocco, Christina S Kong, Roman Diaz, Brian Shin, Hongbin Cao, Andy Trotti, Janine Terra Erler, Christine H Chung, Adam Dicker, Thomas F Pajak, Amato J Giaccia, K Kian Ang

61 Citations (Scopus)

Abstract

PURPOSE: To validate lysyl oxidase (LOX), a hypoxia-related protein, as a marker for metastasis in an independent head and neck cancer (HNC) patient group enrolled onto a prospective trial.

PATIENTS AND METHODS: We performed traditional immunohistochemical (IHC) staining and automated quantitative analysis (AQUA) for LOX expression in 66 HNC patients from one institution. We also performed AQUA staining for LOX in 306 of 1,113 patients treated on a phase III trial comparing four radiation fractionation schedules in locally advanced HNC (RTOG 90-03). Pretreatment characteristics and outcome were similar between patients with and without LOX assessment. We correlated AQUA LOX expression with time to metastasis (TTM), time to progression (TTP), and overall survival (OS).

RESULTS: LOX expression from both staining methods predicted for TTM in the first 66 patients. Multivariate analysis, controlling for significant parameters including nodal stage and performance status, revealed tumor LOX expression, as a continuous variable, was an independent predictor for TTM (hazard ratio [HR], 1.21; 95% CI, 1.10 to 1.33; P = .0001), TTP (HR, 1.06; 95% CI, 1.02 to 1.10; P = .0069), and OS (HR, 1.04; 95% CI, 1.00 to 1.07; P = .0311) in RTOG 90-03 patients. This translates into a 259% increase in metastatic risk for a patient at the 75th percentile of LOX compared with one at the 25th percentile.

CONCLUSION: AQUA LOX expression was strongly associated with increased metastasis, progression, and death in RTOG 90-03 patients. This study validates that LOX is a marker for metastasis and survival in HNC.

Original language	English
Journal	Journal of Clinical Oncology
Volume	27
Issue number	26
Pages (from-to)	4281-6
Number of pages	6
ISSN	0732-183X
DOIs	https://doi.org/10.1200/JCO.2008.20.6003
Publication status	Published - 10 Sept 2009
Externally published	Yes

Keywords

Adult
Aged
Aged, 80 and over
Carcinoma, Squamous Cell
Cause of Death
Disease Progression
Female
Head and Neck Neoplasms
Humans
Immunohistochemistry
Male
Middle Aged
Multivariate Analysis
Neoplasm Metastasis
Prognosis
Proportional Hazards Models
Protein-Lysine 6-Oxidase
Reproducibility of Results
Sensitivity and Specificity
Staining and Labeling
Survival Analysis
Survival Rate
Tumor Markers, Biological

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2008.20.6003

Cite this

Le, Q-T., Harris, J., Magliocco, A. M., Kong, C. S., Diaz, R., Shin, B., Cao, H., Trotti, A., Erler, J. T., Chung, C. H., Dicker, A., Pajak, T. F., Giaccia, A. J., & Ang, K. K. (2009). Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. Journal of Clinical Oncology, 27(26), 4281-6. https://doi.org/10.1200/JCO.2008.20.6003

Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma : Radiation Therapy Oncology Group trial 90-03. / Le, Quynh-Thu; Harris, Jonathan; Magliocco, Anthony M et al.

In: Journal of Clinical Oncology, Vol. 27, No. 26, 10.09.2009, p. 4281-6.

Research output: Contribution to journal › Journal article › Research › peer-review

Le, Q-T, Harris, J, Magliocco, AM, Kong, CS, Diaz, R, Shin, B, Cao, H, Trotti, A, Erler, JT, Chung, CH, Dicker, A, Pajak, TF, Giaccia, AJ & Ang, KK 2009, 'Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03', Journal of Clinical Oncology, vol. 27, no. 26, pp. 4281-6. https://doi.org/10.1200/JCO.2008.20.6003

@article{e61cdee6331c4e0c83bb813e3165ee62,

title = "Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03",

abstract = "PURPOSE: To validate lysyl oxidase (LOX), a hypoxia-related protein, as a marker for metastasis in an independent head and neck cancer (HNC) patient group enrolled onto a prospective trial.PATIENTS AND METHODS: We performed traditional immunohistochemical (IHC) staining and automated quantitative analysis (AQUA) for LOX expression in 66 HNC patients from one institution. We also performed AQUA staining for LOX in 306 of 1,113 patients treated on a phase III trial comparing four radiation fractionation schedules in locally advanced HNC (RTOG 90-03). Pretreatment characteristics and outcome were similar between patients with and without LOX assessment. We correlated AQUA LOX expression with time to metastasis (TTM), time to progression (TTP), and overall survival (OS).RESULTS: LOX expression from both staining methods predicted for TTM in the first 66 patients. Multivariate analysis, controlling for significant parameters including nodal stage and performance status, revealed tumor LOX expression, as a continuous variable, was an independent predictor for TTM (hazard ratio [HR], 1.21; 95% CI, 1.10 to 1.33; P = .0001), TTP (HR, 1.06; 95% CI, 1.02 to 1.10; P = .0069), and OS (HR, 1.04; 95% CI, 1.00 to 1.07; P = .0311) in RTOG 90-03 patients. This translates into a 259% increase in metastatic risk for a patient at the 75th percentile of LOX compared with one at the 25th percentile.CONCLUSION: AQUA LOX expression was strongly associated with increased metastasis, progression, and death in RTOG 90-03 patients. This study validates that LOX is a marker for metastasis and survival in HNC.",

keywords = "Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Cause of Death, Disease Progression, Female, Head and Neck Neoplasms, Humans, Immunohistochemistry, Male, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Prognosis, Proportional Hazards Models, Protein-Lysine 6-Oxidase, Reproducibility of Results, Sensitivity and Specificity, Staining and Labeling, Survival Analysis, Survival Rate, Tumor Markers, Biological",

author = "Quynh-Thu Le and Jonathan Harris and Magliocco, {Anthony M} and Kong, {Christina S} and Roman Diaz and Brian Shin and Hongbin Cao and Andy Trotti and Erler, {Janine Terra} and Chung, {Christine H} and Adam Dicker and Pajak, {Thomas F} and Giaccia, {Amato J} and Ang, {K Kian}",

year = "2009",

month = sep,

day = "10",

doi = "10.1200/JCO.2008.20.6003",

language = "English",

volume = "27",

pages = "4281--6",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "26",

}

TY - JOUR

T1 - Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma

T2 - Radiation Therapy Oncology Group trial 90-03

AU - Le, Quynh-Thu

AU - Harris, Jonathan

AU - Magliocco, Anthony M

AU - Kong, Christina S

AU - Diaz, Roman

AU - Shin, Brian

AU - Cao, Hongbin

AU - Trotti, Andy

AU - Erler, Janine Terra

AU - Chung, Christine H

AU - Dicker, Adam

AU - Pajak, Thomas F

AU - Giaccia, Amato J

AU - Ang, K Kian

PY - 2009/9/10

Y1 - 2009/9/10

N2 - PURPOSE: To validate lysyl oxidase (LOX), a hypoxia-related protein, as a marker for metastasis in an independent head and neck cancer (HNC) patient group enrolled onto a prospective trial.PATIENTS AND METHODS: We performed traditional immunohistochemical (IHC) staining and automated quantitative analysis (AQUA) for LOX expression in 66 HNC patients from one institution. We also performed AQUA staining for LOX in 306 of 1,113 patients treated on a phase III trial comparing four radiation fractionation schedules in locally advanced HNC (RTOG 90-03). Pretreatment characteristics and outcome were similar between patients with and without LOX assessment. We correlated AQUA LOX expression with time to metastasis (TTM), time to progression (TTP), and overall survival (OS).RESULTS: LOX expression from both staining methods predicted for TTM in the first 66 patients. Multivariate analysis, controlling for significant parameters including nodal stage and performance status, revealed tumor LOX expression, as a continuous variable, was an independent predictor for TTM (hazard ratio [HR], 1.21; 95% CI, 1.10 to 1.33; P = .0001), TTP (HR, 1.06; 95% CI, 1.02 to 1.10; P = .0069), and OS (HR, 1.04; 95% CI, 1.00 to 1.07; P = .0311) in RTOG 90-03 patients. This translates into a 259% increase in metastatic risk for a patient at the 75th percentile of LOX compared with one at the 25th percentile.CONCLUSION: AQUA LOX expression was strongly associated with increased metastasis, progression, and death in RTOG 90-03 patients. This study validates that LOX is a marker for metastasis and survival in HNC.

AB - PURPOSE: To validate lysyl oxidase (LOX), a hypoxia-related protein, as a marker for metastasis in an independent head and neck cancer (HNC) patient group enrolled onto a prospective trial.PATIENTS AND METHODS: We performed traditional immunohistochemical (IHC) staining and automated quantitative analysis (AQUA) for LOX expression in 66 HNC patients from one institution. We also performed AQUA staining for LOX in 306 of 1,113 patients treated on a phase III trial comparing four radiation fractionation schedules in locally advanced HNC (RTOG 90-03). Pretreatment characteristics and outcome were similar between patients with and without LOX assessment. We correlated AQUA LOX expression with time to metastasis (TTM), time to progression (TTP), and overall survival (OS).RESULTS: LOX expression from both staining methods predicted for TTM in the first 66 patients. Multivariate analysis, controlling for significant parameters including nodal stage and performance status, revealed tumor LOX expression, as a continuous variable, was an independent predictor for TTM (hazard ratio [HR], 1.21; 95% CI, 1.10 to 1.33; P = .0001), TTP (HR, 1.06; 95% CI, 1.02 to 1.10; P = .0069), and OS (HR, 1.04; 95% CI, 1.00 to 1.07; P = .0311) in RTOG 90-03 patients. This translates into a 259% increase in metastatic risk for a patient at the 75th percentile of LOX compared with one at the 25th percentile.CONCLUSION: AQUA LOX expression was strongly associated with increased metastasis, progression, and death in RTOG 90-03 patients. This study validates that LOX is a marker for metastasis and survival in HNC.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Squamous Cell

KW - Cause of Death

KW - Disease Progression

KW - Female

KW - Head and Neck Neoplasms

KW - Humans

KW - Immunohistochemistry

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Neoplasm Metastasis

KW - Prognosis

KW - Proportional Hazards Models

KW - Protein-Lysine 6-Oxidase

KW - Reproducibility of Results

KW - Sensitivity and Specificity

KW - Staining and Labeling

KW - Survival Analysis

KW - Survival Rate

KW - Tumor Markers, Biological

U2 - 10.1200/JCO.2008.20.6003

DO - 10.1200/JCO.2008.20.6003

M3 - Journal article

C2 - 19667273

SN - 0732-183X

VL - 27

SP - 4281

EP - 4286

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 26

ER -

Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this